(NASDAQ: BRNS) Barinthus Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.71%.
Barinthus Biotherapeutics's earnings in 2025 is -$65,233,000.On average, 2 Wall Street analysts forecast BRNS's earnings for 2025 to be -$60,105,699, with the lowest BRNS earnings forecast at -$65,753,214, and the highest BRNS earnings forecast at -$54,458,183. On average, 2 Wall Street analysts forecast BRNS's earnings for 2026 to be -$58,088,729, with the lowest BRNS earnings forecast at -$68,173,578, and the highest BRNS earnings forecast at -$48,003,880.
In 2027, BRNS is forecast to generate -$80,275,396 in earnings, with the lowest earnings forecast at -$80,275,396 and the highest earnings forecast at -$80,275,396.